142 related articles for article (PubMed ID: 5335155)
1. Effects of L-DOPA on pharmacological parkinsonism.
Bruno A; Bruno SC
Acta Psychiatr Scand; 1966; 42(3):264-71. PubMed ID: 5335155
[No Abstract] [Full Text] [Related]
2. A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Ekdawi MY; Fowke R
Br J Psychiatry; 1966 Jun; 112(487):633-6. PubMed ID: 5964267
[No Abstract] [Full Text] [Related]
3. The pharmacology of parkinsonism (a review).
Klawans HL
Dis Nerv Syst; 1968 Dec; 29(12):805-16. PubMed ID: 4388368
[No Abstract] [Full Text] [Related]
4. L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression.
Kimura N; Tsukue I
Hiroshima J Med Sci; 1971 Mar; 20(1):55-63. PubMed ID: 5121129
[No Abstract] [Full Text] [Related]
5. Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population.
Martin IC
Acta Psychiatr Scand; 1975 Feb; 51(2):110-8. PubMed ID: 235189
[TBL] [Abstract][Full Text] [Related]
6. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
Kelly JT; Zimmermann RL; Abuzzahab FS; Schiele BC
Pharmacology; 1974; 12(2):65-73. PubMed ID: 4610599
[No Abstract] [Full Text] [Related]
7. Treatment of Parkinsonism with L-dopa.
Presthus J
Acta Neurol Scand; 1970; 46(S43):220. PubMed ID: 4917684
[No Abstract] [Full Text] [Related]
8. [Evaluation of L-DOPA in Parkinsonism with special reference to the study by double-blind method].
Okajima T; Kubota A; Nakahara N; Takeda S; Shimomura K
Naika; 1972; 29(2):335-43. PubMed ID: 4552443
[No Abstract] [Full Text] [Related]
9. A comparison of haloperidol and thioridazine HC1 in chronic treatment-resistant schizophrenics.
Gonier T; Schiele BC; Vestre ND
Behav Neuropsychiatry; 1970; 2(3):47-9 passim. PubMed ID: 4913152
[No Abstract] [Full Text] [Related]
10. Oral L-dopa treatment of parkinsonism.
Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
[No Abstract] [Full Text] [Related]
11. [The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Arushanian EB; Stoliarov GV; Tolpyshev BA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(9):1384-8. PubMed ID: 5511122
[No Abstract] [Full Text] [Related]
12. [On the results of treatment and complications during the use of haloperidol in patients with long-term schizophrenia].
Zolotnitskii RI; Kutsenok BM; Gastev MD
Zh Nevropatol Psikhiatr Im S S Korsakova; 1969; 69(5):750-4. PubMed ID: 5363890
[No Abstract] [Full Text] [Related]
13. Parkinsonism and DOPA.
Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB
Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342
[No Abstract] [Full Text] [Related]
14. Combined treatment of parkinsonism with L-dopa and amantadine.
Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
[No Abstract] [Full Text] [Related]
15. [Therapy of parkinsonian syndromes with L-dopa. Results and prospects].
Fazio C
Sist Nerv; 1970; 22(2):61-6. PubMed ID: 5504558
[No Abstract] [Full Text] [Related]
16. The influence of L-dopa on physical treatment of Parkinsonism.
Mikkelsen B; Dupont E; Worm-Petersen J
Acta Neurol Scand Suppl; 1972; 51():127-8. PubMed ID: 4576069
[No Abstract] [Full Text] [Related]
17. [Etiology and therapy of Parkinson's syndrome and related pharmacological concepts shown in experimental models].
Oehme P; Schwarz K
Dtsch Gesundheitsw; 1966 Apr; 21(17):792-8. PubMed ID: 5929188
[No Abstract] [Full Text] [Related]
18. Parkinsonism by haloperidol and piribedil.
Corsini GU; Del Zompo M; Spissu A; Mangoni A; Gessa GL
Psychopharmacology (Berl); 1978 Oct; 59(2):139-41. PubMed ID: 103114
[TBL] [Abstract][Full Text] [Related]
19. Effects of L-dopa in Parkinson's disease.
Godwin-Austen RB; Tomlinson EB; Frears CC; Kok HW
Lancet; 1969 Jul; 2(7613):165-8. PubMed ID: 4183130
[No Abstract] [Full Text] [Related]
20. [Parkinson's syndrome and L-dopa].
Pompeu F; Sztajnberg M; Teixeira I; Carneiro S; Schulz I; Ribeiro S; Vasconcelos H; Albuquerque E
Arq Neuropsiquiatr; 1971 Jun; 29(2):174-83. PubMed ID: 4946063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
